Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection

CNS Drugs

Volumn 26, Issue 10, 2012, Pages 871-882

  Hlscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimers disease; Amyotrophic lateral sclerosis; Glucagon like peptide 1; Ischaemia; Multiple sclerosis; Neurodegenerative disorders; Parkinsons disease; Stroke.

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PLACEBO;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIA; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STROKE; SYNAPSE;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84865849218     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11635890-000000000-00000     Document Type: Review

References (97)

1. Hö lscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 1998; 5 (3): 129-41
2. Bossy WE, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10 Suppl.: S2-9
3. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010; 159 (3): 495-501
4. Aharoni R. Immunomodulatory drug treatment in multiple sclerosis. Exp Rev Neurother 2010; 10 (9): 1423-36
5. Chen SY, Chen TF, Lai LC, et al. Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation 2012; 9 (1): 21-9
6. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995; 10: 19-45
7. Holmes C, Cunningham C, Zotova E, et al. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 2011; 77 (3): 212-8
8. Ziabreva I, Perry E, Perry R, et al. Altered neurogenesis in Alzheimer's disease. J Psychosom Res 2006; 61 (3): 311-6
9. Korecka JA, Verhaagen J, Hol EM. Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. Regen Med 2007; 2 (4): 425-46
10. McClean P, Parthsarathy V, Faivre E, et al. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011; 31: 6587-94
11. Moroo I, Yamada T, Makino H, et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol (Berl) 1994; 87 (4): 343-8
12. Aviles-Olmos I, Limousin P, Lees A, et al. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain. Epub 2012 Feb 17
13. Strachan MW. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem Soc Trans 2005; 33 (Pt 5): 1037-40
14. Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006; 2 (3): 159-66
15. Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63 (7): 1187-92
16. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82 (8): 510-29
17. Biessels GJ, De Leeuw FE, Lindeboom J, et al. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006; 77 (3): 304-7
18. Janson J, Laedtke T, Parisi J, et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-81
19. Carro E, Torres-Aleman I. Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects? Expert Rev Neurother 2004; 4 (1): 79-86
20. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004; 490 (1-3): 115-25
21. Steen E, Terry BM, Rivera E, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease: is this type 3 diabetes? J Alzheimers Dis 2005; 7 (1): 63-80
22. Lester-Coll N, Rivera EJ, Soscia SJ, et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006; 9 (1): 13-33
23. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122 (4): 1316-38
24. Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010; 31 (2): 224-43
25. Klein W, Barlow A, Chrimy B, et al., editors. "ADDLS"-soluble Ab oligomers that cause biphasic loss of hippocampal neuron function and survival. Society for Neuroscience 27th Annual Meeting; 1997 Oct 25-29; New Orleans (LA)
26. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009; 106 (6): 1971-6
27. Morris JK, Zhang H, Gupte AA, et al. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res 2008; 1240: 185-95
28. Morris JK, Bomhoff GL, Gorres BK, et al. Insulin resistance impairs nigrostriatal dopamine function. Exp Neurol 2011; 231 (1): 171-80
29. Benomar Y, Naour N, Aubourg A, et al. Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase-dependent mechanism. Endocrinology 2006; 147 (5): 2550-6
30. Grillo CA, Piroli GG, Hendry RM, et al. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 2009; 1296: 35-45
31. Hoyer S. Models of Alzheimer's disease: cellular and molecular aspects. J Neural Transm 1997; 49 (11): 11-21
32. Biessels GJ, Bravenboer B, Gispen WH. Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur J Pharmacol 2004; 490 (1-3): 1-4
33. Zhao AZ, Shinohara MM, Huang D, et al. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem 2000; 275 (15): 11348-54
34. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006; 9 (2): 167-81
35. Hö lscher C. Synaptic plasticity and learning and memory: LTP and beyond. J Neurosci Res 1999; 58: 62-75
36. Stockhorst U, de Fries D, Steingrueber HJ, et al. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 2004; 83 (1): 47-54
37. Holscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci 2005; 16 (3): 181-212
38. Li L, Hö lscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56: 384-402
39. van Dam P, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol 2004; 490 (1-3): 87-95
40. Carro E, Torres AI. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004; 490 (1-3): 127-33
41. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004; 490 (1-3): 97-113
42. Zhao WQ, Chen H, Quon MJ, et al. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004; 490 (1-3): 71-81
43. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008; 13 (3): 323-31
44. Okereke OI, Selkoe DJ, Pollak MN, et al. A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int J Geriatr Psychiatry 2008; 24: 177-82
45. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70 (6): 440-8
46. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007; 4 (2): 147-52
47. Craft S. A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early Alzheimer's [abstract no. P3-455]. ICAD Conference; 2010 Jul 10-15; Honolulu (HI)
48. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010; 5: 109-17
49. Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 2010; 31: 1495-502
50. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011; 39 (4): 891-7
51. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368 (9548): 1696-705
52. Holst JJ. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004; 9 (1): 155-66
53. Green BD, Gault VA, Flatt PR, et al. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 2004; 428 (2): 136-43
54. Green BD, Flatt PR. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 2007; 21 (4): 497-516
55. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9 (9): 1173-9
56. Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007; 203 (2): 293-301
57. Hamilton A, Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009; 20: 1161-6
58. Iwai T, Ito S, Tanimitsu K, et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res 2006; 55 (4): 352-60
59. Gault V, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by betaamyloid. Eur J Pharmacol 2008; 587: 112-7
60. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27 (3): 313-8
61. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagonlike peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18 (1-2): 7-14
62. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13 (1): 33-8
63. McGovern S, Kerry H, Holscher C. Effects of the glucagonlike polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Res. In press
64. Gengler S, McClean P, McCurtin R, et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2012; 33: 265-76
65. Wang XH, Li L, Holscher C, et al. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010; 170 (4): 1239-48
66. Han W-N, Holscher C, Yuan L, et al. Liraglutide protects against amyloid-X protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging. Epub 2012 May 14
67. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008; 25 (9): 1129-31
68. McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010; 630: 158-62
69. Perry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302 (3): 881-8
70. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003; 72 (5): 603-12
71. Li Y, Duffy K, Ottinger M, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010; 19: 1205-19
72. Porter DW, Irwin N, Flatt PR, et al. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol 2010; 650 (2-3): 688-93
73. Porter DW, Kerr BD, Flatt PR, et al. Four weeks administration of liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab 2010; 12 (10): 891-9
74. Hamilton A, Patterson S, Porter D, et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 2011; 89 (4): 481-9
75. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 2007; 30 (9): 464-72
76. Bradbury J. Hope for AD with NGF gene-therapy trial. Lancet Neurol 2005; 4 (6): 335-42
77. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429 (6990): 413-7
78. Gregory-Evans K, Chang F, Hodges MD, et al. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vis 2009; 15: 962-73
79. Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86 (2): 326-38
80. Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008; 5: 19-31
81. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106 (4): 1285-90
82. Pressley JC, Louis ED, Tang MX, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 2003; 60 (1): 87-93
83. Kunst C. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75: 933-47
84. Li Y, Chigurupati S, Holloway HW, et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012; 7 (2): e32008
85. Knippenberg S, Thau N, Dengler R, et al. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide-1 prolongs survival in a mouse model of ALS. PLoS ONE 2012; 7 (6): e36857
86. Himeno T, Kamiya H, Naruse K, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011; 60 (9): 2397-406
87. Ayasolla K, Khan M, Singh AK, et al. Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med 2004; 37 (3): 325-38
88. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59 (4): 1030-7
89. Dozier KC, Cureton EL, Kwan RO, et al. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009; 30 (9): 1735-41
90. Parsarathy V, Holscher C, editors. The novel GLP1 analogue, liraglutide, reduces inflammation in a mouse model of brain tissue injury. Washington, DC: Society for Neuroscience Annual Meeting, 2011
91. Lee CH, Yan B, Yoo KY, et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011; 89 (7): 1103-13
92. Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011; 31 (8): 1696-705
93. Rossi S, Furlan R, De Chiara V, et al. Interleukin-1beta causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol 2012; 71 (1): 76-83
94. Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm 2009; 116 (11): 1443-9
95. Aharoni R, Vainshtein A, Stock A, et al. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J Autoimmun 2011; 37 (3): 228-41
96. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124 (1 Suppl.): S3-18
97. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33 (2): 187-215